ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 557,77
0,55%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) Actualités

OLMA Olema Pharmaceuticals Inc

12,36
-0,10 (-0,80%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Olema Pharmaceuticals Inc OLMA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,10 -0,80% 12,36 06:00:09
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
12,37 12,14 12,78 12,36 12,46
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202422:39EDGAR2Form 8-K - Current report
07/6/202400:49EDGAR2Form SC 13D/A - General statement of acquisition of..
06/6/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202416:05EDGAR2Form 144 - Report of proposed sale of securities
06/6/202416:02EDGAR2Form 144 - Report of proposed sale of securities
05/6/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:28GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
04/6/202421:09EDGAR2Form 144 - Report of proposed sale of securities
03/6/202420:55EDGAR2Form 144 - Report of proposed sale of securities
31/5/202418:17EDGAR2Form 144 - Report of proposed sale of securities
28/5/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202413:03GLOBEOlema Oncology to Participate in Upcoming Investor..
15/5/202413:06EDGAR2Form 8-K - Current report
15/5/202413:01GLOBEOlema Oncology Announces Promising New Data for Palazestrant..
08/5/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:06EDGAR2Form 8-K - Current report
08/5/202422:02GLOBEOlema Oncology Reports First Quarter 2024 Financial Results..
08/5/202413:02GLOBEOlema Oncology Announces New Clinical Data for Palazestrant..
07/5/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:00EDGAR2Form 144 - Report of proposed sale of securities
02/5/202422:37GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/5/202413:02GLOBEOlema Oncology to Participate in Upcoming Investor..
08/4/202422:30GLOBEOlema Oncology to Participate in Canaccord Genuity 2024..
02/4/202422:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
11/3/202421:31EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202421:05EDGAR2Form 8-K - Current report
11/3/202421:03GLOBEOlema Oncology Reports Fourth Quarter and Full-Year 2023..
06/3/202413:03GLOBEOlema Oncology Announces Publication of Data Highlighting..
04/3/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
29/2/202420:26EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/2/202413:01GLOBEOlema Oncology to Participate in Upcoming Investor..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/2/202421:24EDGAR2Form 144 - Report of proposed sale of securities
31/1/202422:21EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202420:58EDGAR2Form 144 - Report of proposed sale of securities
29/1/202413:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:07EDGAR2Form 8-K - Current report
08/1/202414:18EDGAR2Form 8-K - Current report
08/1/202414:12GLOBEOlema Oncology Nominates OP-3136, an Orally Bioavailable..
05/1/202423:26EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
OLMA
Olema Pharmaceuticals
BIT
P1XPK0
NLBNPIT1XPK0 20991231 70...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés